Generic name: DESMOPRESSIN ACETATE 4ug in 1mL
Dosage form: injection
Medically reviewed by Drugs.com. Last updated on Aug 22, 2018.
Hemophilia A and von Willebrand's Disease (Type I)
DDAVP Injection 4 mcg/mL is administered as an intravenous infusion at a dose of 0.3 mcg DDAVP/kg body weight diluted in sterile physiological saline and infused slowly over 15 to 30 minutes. In adults and children weighing more than 10 kg, 50 mL of diluent is recommended; in children weighing 10 kg or less, 10 mL of diluent is recommended. Blood pressure and pulse should be monitored during infusion. If DDAVP Injection 4 mcg/mL is used preoperatively, it should be administered 30 minutes prior to the scheduled procedure.
The necessity for repeat administration of DDAVP or use of any blood products for hemostasis should be determined by laboratory response as well as the clinical condition of the patient. The tendency toward tachyphylaxis (lessening of response) with repeated administration given more frequently than every 48 hours should be considered in treating each patient.
This formulation is administered subcutaneously or by direct intravenous injection. DDAVP Injection 4 mcg/mL dosage must be determined for each patient and adjusted according to the pattern of response. Response should be estimated by two parameters: adequate duration of sleep and adequate, not excessive, water turnover.
The usual dosage range in adults is 0.5 mL (2.0 mcg) to 1 mL (4.0 mcg) daily, administered intravenously or subcutaneously, usually in two divided doses. The morning and evening doses should be separately adjusted for an adequate diurnal rhythm of water turnover. For patients who have been controlled on intranasal DDAVP and who must be switched to the injection form, either because of poor intranasal absorption or because of the need for surgery, the comparable antidiuretic dose of the injection is about one-tenth the intranasal dose.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See CLINICAL PHARMACOLOGY, Human Pharmcokinetics, CONTRAINDICATIONS, and PRECAUTIONS, Geriatric Use.)
Directions for use of One Point Cut (OPC) Ampules for DDAVP Injection
- Use aseptic technique to clean ampule. Gently tap the top of the ampule to assist the flow of the solution from the upper portion of the ampule to the lower portion.
- Locate the blue dot on the upper portion of the ampule. Below this dot is a small score on the neck of the ampule. Hold the ampule with the blue dot facing away from you.
- Cover the vial with an appropriate wipe. Apply pressure to the top and bottom portions of the ampule to snap the ampule open away from you.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about DDAVP (desmopressin)
- Side Effects
- During Pregnancy or Breastfeeding
- Drug Images
- Drug Interactions
- Compare Alternatives
- Pricing & Coupons
- 9 Reviews
- Generic Availability
- Drug class: antidiuretic hormones
- FDA Alerts (1)
- DDAVP injection
- DDAVP nasal
- DDAVP (Desmopressin Injection Solution)
- DDAVP (Desmopressin Tablets)
- DDAVP (Advanced Reading)
- ... +2 more